Fierce Pharma

JULY 2, 2024

After turning down Eli Lilly’s Alzheimer’s disease drug donanemab for an accelerated approval last year, the agency has now offered the anti-amyloid therapy—and a competitor to Eisai and Bioge | After turning down Eli Lilly’s Alzheimer’s disease drug donanemab for an accelerated approval last year, the agency has now offered the anti-amyloid therapy, a competitor to Eisai and Biogen’s Leqembi, a full approval.

FDA 347

FDA 347

pharmaphorum

JULY 2, 2024

Sobi starts rolling application for refractory gout drug SEL-212 in the US, hoping to take on Amgen’s Krystexxa in the market.

FDA 135

FDA Marketing 135

David Bagga

JULY 1, 2024

Medical Device Sales Academy What Degree is Best For Medical Sales? The healthcare industry, a significant driver of the economy and a key player in improving people’s lives, is poised for continued growth. This expansion is fueled by the increasing demand for healthcare services and tools, driven by an aging population and prevalent illnesses.

Medical sales 130

Medical sales Medical Sales Healthcare 130

MedCity News

JULY 2, 2024

Eli Lilly’s Kisunla is now FDA approved for treating patients in the early stages of Alzheimer’s disease. In addition to slowing cognitive decline and disease progression, clinical trial results showed that amyloid beta plaques were reduced to the point where some patients could stop taking the infused therapy. The post Eli Lilly Alzheimer’s Drug Lands FDA Approval, Introducing Competition to Eisai’s Leqembi appeared first on MedCity News.

Competition 126

Competition FDA Patients Biopharma 126

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

JULY 3, 2024

After more than a decade with no treatment advances for chronic obstructive pulmonary disease (COPD), two have been approved by regulators on either side of the Atlantic within a week. | After more than a decade with no treatment advances for chronic obstructive pulmonary disease (COPD), two have been approved by regulators on either side of the Atlantic within a week.

Medicine 302

Medicine Patients 302

PharmaTimes

JULY 5, 2024

The neurodegenerative disease currently affects more than 200,000 people worldwide

Leads 120

Leads 120

MedCity News

JULY 2, 2024

Primary care physicians are generally pretty optimistic about AI’s potential to make care delivery more efficient, according to new survey results. In the past few years, automated dictation and scribing tools were the AI technologies that have been most impactful for primary care providers. The post Why Are Primary Care Physicians Optimistic About AI?

Physicians 122

Physicians 122

Fierce Pharma

JULY 2, 2024

In recent months, frequent pharma critic Sen. | As the November U.S. elections near, it's clear that drug pricing will remain an important topic for voters and politicians. In a Tuesday op-ed, President Joe Biden and Sen. Bernie Sanders placed a spotlight on Novo Nordisk and Eli Lilly's drug pricing.

Pharma 289

Pharma 289

pharmaphorum

JULY 2, 2024

The field of muscle stem cell research has been tangibly developing over the decades and in today’s pharmaphorum podcast wed editor Nicole Raleigh speaks with Dr Michael Rudnicki, co-founder and CSO of Satellos Biosciences, a company dedicated to developing novel therapeutics based on this science for those who live with Duchenne muscular dystrophy (DMD) and other degenerative muscle diseases.

Medicine 118

Medicine 118

European Pharmaceutical Review

JULY 4, 2024

Altering the conditions that T cells are grown in can improve CAR T-cell therapy, US researchers have found. Discovered by chance, their new method has potential to treat solid cancer tumours more efficiently, according to the findings. Putting T cells on a keto diet [putting our T cells on a three-day ‘keto’ diet] showed reduced maturity at the end of the manufacturing process.

Media 116

Media Leads Manufacturing Patients 116

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

MedCity News

JUNE 30, 2024

By being aware of the latest schemes, health plan leaders can ensure their members have appropriate access to care while preventing bad actors from exploiting telehealth policies established during the pandemic. The post Mental Health Fraud Schemes: How to Protect Your Plan appeared first on MedCity News.

122

122

Fierce Pharma

JULY 2, 2024

The world’s first injectable immune checkpoint inhibitor likely won’t make it to the U.S. | The world’s first injectable immune checkpoint inhibitor likely won’t make it to the U.S. anytime soon, after the China-approved drug flunked a pivotal trial in a rare cancer, forcing its stateside developer Tracon to explore strategic alternatives.

285

285

pharmaphorum

JULY 1, 2024

France's HAS agrees to fund treatment with Carthera's ultrasound device for French subjects enrolled in a glioblastoma trial.

116

116

Pharmaceutical Technology

JULY 2, 2024

The EMA has accepted AstraZeneca's MAA for sipavibart as Covid-19 pre-exposure prophylaxis (prevention) in immunocompromised patients.

Patients 116

Patients 116

Advertisement

MedCity News

JULY 3, 2024

Abbott recently launched the FreeStyle Libre 3 Plus sensor, which it says is the smallest and most discreet sensor on the market. It will soon be available in U.S. retail pharmacies and medical equipment suppliers. The post Abbott Says Its Latest CGM Sensor Is Its Most Discreet Yet appeared first on MedCity News.

Retail 121

Retail Medical Marketing 121

Fierce Pharma

JULY 1, 2024

GSK scratched another Zantac lawsuit off the list with a confidential settlement in Illinois as it continues to work through the mountain of personal injury litigation related to the heartburn pill | Following a win and a separate dismissal in Illinois, GSK agreed to a confidential settlement to resolve prostate cancer claims put forward by plaintiff Martin Gross.

284

284

pharmaphorum

JULY 4, 2024

Pieris' immuno-oncology alliance with Servier is being dissolved after a trial of the lead drug in the alliance revealed a safety concern.

Safety 115

Safety Leads 115

PharmaTimes

JULY 5, 2024

Pneumococcus is the leading cause of pneumonia, meningitis and sepsis worldwide

Leads 111

Leads 111

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

MedCity News

JULY 3, 2024

The Rise Fund will lead a $200 million investment in Foodsmart. The funding will help the telenutrition company scale its business. The post Foodsmart Snags $200M Investment Led By TPG’s Rise Fund appeared first on MedCity News.

Leads 121

Leads Food 121

Fierce Pharma

JULY 2, 2024

With four contract modifications totaling more than $250 million, the government is leveling up its agreements with long-time medical countermeasures supplier Emergent BioSolutions. | The drugmaker will supply its anthrax vaccine Cyfendus, its smallpox vaccine and two other drugs to help bolster the U.S. government's medical countermeasures stockpile.

Medical 279

Medical Government 279

pharmaphorum

JULY 1, 2024

AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP).The drugmaker said this morning that an application for sipavibart (AZD3152) has been accepted for review by the EMA as PrEP for immunocompromised patients who often do not respond adequately to vaccination alone and remain at high risk of serious outcomes from COVID-19.

Marketing 116

Marketing Patients 116

PharmaTimes

JULY 1, 2024

Breast cancer is the most common cancer in the UK, accounting for 15% of all cancers

106

106

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

MedCity News

JULY 3, 2024

GSK is taking over development of an avian influenza vaccine candidate as a bird flu outbreak continues in U.S. dairy cows. Meanwhile, CureVac is restructuring and returning its attention to cancer vaccines, which was the initial focus of the mRNA company. The post GSK Pays CureVac €400M to Pick Up Clinical-Stage mRNA Vaccines for Infectious Diseases appeared first on MedCity News.

Biopharma 121

Biopharma Pharma 121

Fierce Pharma

JULY 2, 2024

Even as the BIOSECURE Act charts an uncertain path through the legislative process, the draft bill has already seriously harmed the U.S. | Even as the BIOSECURE Act works its way through the legislative process, the draft bill has already caused a slide in U.S. life sciences companies' confidence in Chinese partners, a new survey has found.

Biopharma 279

Biopharma 279

pharmaphorum

JULY 2, 2024

The FTC is reported to have opened an investigation into Teva focusing on improperly listed patents in the FDA’s Orange Book

115

115

PharmaTimes

JULY 4, 2024

Aggressive prostate cancer accounts for up to 15% of all prostate cancer diagnoses

106

106

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

MedCity News

JULY 5, 2024

In our eagerness for innovation, there’s a risk that we ignore existing effective, readily-available treatments. The post Why Wait? The Urgency of Accessible PTSD Treatments Now appeared first on MedCity News.

118

118

Fierce Pharma

JULY 2, 2024

In a major win for Johnson & Johnson and Legend Biotech, their star CAR-T therapy Carvykti showed it can prolong the lives of patients with previously treated multiple myeloma. | In a major win for J&J and Legend, their star CAR-T therapy Carvykti showed it can prolong the lives of patients with previously treated multiple myeloma.

Patients 277

Patients 277

pharmaphorum

JULY 4, 2024

UK survey finds more than two-thirds of people with chronic hand eczema say it has affected their relationships and/or working life.

114

114

Pharmaceutical Technology

JULY 2, 2024

Leqembi will now face a challenger as donanemab enters the market under the brand name Kisunla.

FDA 105

FDA Marketing 105

Advertisement

Distribution